DV, 3.3 mm) of C57 mice bilaterally, and rAAV2/9-VGAT1-DIO-hM4D(Gi)-mCherry-WPRE-hGH-pA (5.02E + 12 vg/ml, Cat
1) [4, 5], and include dysfunction of adipocytes (accelerated lipolysis), the gastrointestinal tract and entero-endocrine system (incretin deficiency/resistance), -cells (hyperglucagonemia), kidneys (increased glucose reabsorption), and brain (neurotransmitter dysfunction)
Oral, once-daily GLP-1 receptor partial agonist No strict fasting requirement (unlike oral Semaglutide) Simplified administration better patient adherence A potential alternative to injectable incretin therapies Clinical Impact Supported by 72-week RCTs Demonstrated statistically significant and clinically meaningful weight loss vs placebo Benefits amplified with lifestyle modification Dosing Approach (Stepwise Escalation) Initiation at low dose with gradual titration every 30 days to improve tolerability and optimize outcomes
Farxiga (dapagliflozin): Another SGLT2 inhibitor showing reductions in heart failure and renal complications, reinforcing the value of this class in high-risk patients
These headaches are typically mild to moderate in severity and tend to improve over time as the body adjusts to the medication
Potentially serious side effects of angioedema and cholestatic jaundice were reported rarely